Physician profile
James G Ryan
NPI 1881608446
$2,608.61
in general payments reported to CMS, 2019-2025
19 companies · $66.53 in 2025
The $66.53 reported for 2025 was more than what a typical Emergency Medicine provider received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $318 · 2020: $72.10 · 2021: $154 · 2022: $702 · 2023: $842 · 2024: $454 · 2025: $66.53.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,362.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,362.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $518.52 | 2021-2024 | Teflaro, Avycaz |
| Janssen Pharmaceuticals, INC | $477.27 | 2019-2024 | Xarelto |
| Pfizer INC. | $400.10 | 2019-2024 | |
| Melinta Therapeutics, LLC | $313.19 | 2021-2025 | Kimyrsa, Orbactiv, Vabomere |
| E.R. Squibb & Sons, L.L.C. | $163.15 | 2022-2025 | Eliquis, Camzyos |
| Merck Sharp & Dohme LLC | $146.70 | 2019-2025 | Zerbaxa, Recarbrio, Dificid |
| Allergan, INC. | $137.40 | 2019-2020 | |
| Gilead Sciences, INC. | $98.63 | 2023-2024 | |
| Astrazeneca Pharmaceuticals Lp | $80.73 | 2023-2024 | Andexxa |
| Shionogi INC | $54.39 | 2022-2023 | Fetroja |
| Bioxcel Therapeutics, INC. | $52.46 | 2023 | Igalmi |
| Chiesi USA, INC. | $38.51 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $25.12 | 2023 | Dupixent |
| Reprise Biomedical, INC. | $23.46 | 2023 | Miro3d |
| Paratek Pharmaceuticals, INC. | $19.92 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.65 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $14.97 | 2023 | Caldolor |
| La Jolla Pharmaceutical Company | $14.30 | 2023 | Xerava |
| Acelrx Pharmaceuticals, INC. | $12.14 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Ryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.